Alex Cocleaza

Alex Cocleaza, MS, MBA, serves as the Head of Therapeutics BU Corporate Development and Enterprise Strategy at 23andMe. Previously, Alex held the position of Advisory Board Member at Patients Capital Management LLC. As the Senior Director of Pharma Partnering for insitro, Alex focused on Central Nervous System, Metabolic, and Oncology sectors. During graduate studies at Harvard, Alex worked as a Biotech VC at F-Prime Capital, specializing in Oncology, Artificial Intelligence for Drug Development, and Women's Health. Earlier in the career, Alex was the Director of Corporate Development and Strategy at Aimmune Therapeutics, where responsibilities included managing immunology-related activities, an IPO, and the acquisition process.